Is There Really a Case for Promiscuous Drugs in Anticancer Therapy

1 Is There Really a Case for Promiscuous Drugs in Anticancer Therapy  

Fernandez, Transformative Concepts for Drug Design Target Wrapping, 

The safety of less selective dmgs, and especially that of promiscuous kinase inhibitors, is often addressed by assessing the full extent of their cross-reactivity [19], This assessment has been facilitated by novel high-throughput screening 

---